跳至主要内容
临床试验/CTRI/2025/08/092687
CTRI/2025/08/092687尚未招募2/3 期

Evaluation of comparative efficacy of Haridradi Siddha Paya Parishek with Anu Tail Marsha Nasya versus Standard Treatment Protocol in the Management of Meibomian Gland Dysfunction (Shushkakshipaka): Randomized Clinical Trial

Dr Prajwal Dilip Piprewar1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2025年9月18日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
发起方
入组人数
54
试验地点
1
主要终点
Improvement in clinical symptoms of Shushkakshipaka

研究概览

简要总结

The study titled Evaluation of comparative efficacy of Haridradi Siddha Paya Parishek with Anu Tail Marsha Nasya versus Standard Treatment Protocol in the Management of Meibomian Gland Dysfunction Shushkakshipaka is a randomized clinical trial conducted to assess Ayurvedic interventions for Dry Eye Syndrome  It compares the therapeutic effects of traditional Ayurvedic treatments Haridradi Siddha Paya Parisheka and Anu Tail Nasya with conventional allopathic methods The trial involves 54 patients divided into two groups and measures outcomes like tear film stability gland function and symptom relief. The aim is to validate Ayurvedic methods as cost-effective holistic alternatives for managing Meibomian Gland Dysfunction Results may encourage the integration of Ayurveda into routine ophthalmic care

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patients of age 18 years to 60 years will be selected irrespective of their gender caste religion socio-economic or educational status Patient suffering from Dry Eye Syndrome Patients with Myopia and Hypermetropia will be selected Patients with anatomically normal ocular structures will be selected Patients who are ready to accept the treatment will be selected Written Consent.

排除标准

  • 未提供

结局指标

主要结局

Improvement in clinical symptoms of Shushkakshipaka

时间窗: Day 0 (Baseline) | Day 15 (Mid-treatment Follow-up) | Day 30 (Final Assessment)

dryness irritation itching photophobia Tear Film Break-Up Time

时间窗: Day 0 (Baseline) | Day 15 (Mid-treatment Follow-up) | Day 30 (Final Assessment)

次要结局

  • improvement in Meibomian Gland Expression Test(Schirmer’s Test)

研究者

发起方
Dr Prajwal Dilip Piprewar
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Prajwal Dilip Piprewar

Mahatma Gandhi Ayurvedic College and Research Centre Salod Wardha

研究点 (1)

Loading locations...

相似试验